Trials / Active Not Recruiting
Active Not RecruitingNCT06854094
Consolidation Therapy With Cladribine in Relapsing Multiple Sclerosis Patients
Consolidation Therapy With Immune Reconstitution Therapy (Cladribine) in Relapsing Multiple Sclerosis Patients Following a Treatment With Anti-CD20 Compounds: a Pivotal Study
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 70 (estimated)
- Sponsor
- Ente Ospedaliero Cantonale, Bellinzona · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To investigate the impact on IgG and IgM concentration, infection risk and effectiveness of switching from anti-CD20 to cladribine compared to continued anti-CD20 treatment over 2 years in relapsing MS patients.
Conditions
Timeline
- Start date
- 2024-10-03
- Primary completion
- 2026-12-01
- Completion
- 2028-12-01
- First posted
- 2025-03-03
- Last updated
- 2026-03-12
Locations
1 site across 1 country: Switzerland
Source: ClinicalTrials.gov record NCT06854094. Inclusion in this directory is not an endorsement.